Karuna Therapeutics (KRTX) Stock Forecast, Price & News

Karuna Therapeutics (NASDAQ:KRTX) Frequently Asked Questions

Is Karuna Therapeutics a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Karuna Therapeutics stock.
View analyst ratings for Karuna Therapeutics or view top-rated stocks.

When is Karuna Therapeutics' next earnings date?

Karuna Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Karuna Therapeutics.

How were Karuna Therapeutics' earnings last quarter?

Karuna Therapeutics, Inc. (NASDAQ:KRTX) released its quarterly earnings results on Thursday, May, 5th. The company reported ($1.95) EPS for the quarter, topping analysts' consensus estimates of ($2.10) by $0.15. During the same period in the previous year, the business posted ($1.10) earnings per share.
View Karuna Therapeutics' earnings history.

What price target have analysts set for KRTX?

9 analysts have issued 12 month price objectives for Karuna Therapeutics' stock. Their forecasts range from $152.00 to $190.00. On average, they expect Karuna Therapeutics' stock price to reach $176.22 in the next twelve months. This suggests a possible upside of 68.6% from the stock's current price.
View analysts' price targets for Karuna Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Karuna Therapeutics' key executives?

Karuna Therapeutics' management team includes the following people:

• Dr. Steven M. Paul M.D., CEO, Pres & Chairman (Age 71, Pay $1.2M)
• Dr. Andrew Craig Miller, Co-Founder & COO (Age 40, Pay $789.55k) (LinkedIn Profile)
• Dr. Troy A. Ignelzi, CFO & Sec. (Age 54, Pay $705.3k) (LinkedIn Profile)
• Dr. Stephen K. Brannan, Chief Medical Officer (Age 66, Pay $737.7k) (LinkedIn Profile)
• Ms. Charmaine Lykins, Chief Commercial Officer
• Dr. Alan Breier, Chair of Scientific Advisory Board & Chief Clinical Advisor

Who are some of Karuna Therapeutics' key competitors?

Some companies that are related to Karuna Therapeutics include Elanco Animal Health (ELAN), Biohaven Pharmaceutical (BHVN), Organon & Co. (OGN), Teva Pharmaceutical Industries (TEVA), Jazz Pharmaceuticals (JAZZ), Grifols (GRFS), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), Maravai LifeSciences (MRVI), Legend Biotech (LEGN), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Intra-Cellular Therapies (ITCI), Ascendis Pharma A/S (ASND) and Acerus Pharmaceuticals (ASPCF).
View all of KRTX's competitors.

What other stocks do shareholders of Karuna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Pfizer (PFE), Alibaba Group (BABA), Johnson & Johnson (JNJ), AT&T (T), Target (TGT) and Walt Disney (DIS).

When did Karuna Therapeutics IPO?

(KRTX) raised $70 million in an IPO on Friday, June 28th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Karuna Therapeutics' stock symbol?

Karuna Therapeutics trades on the NASDAQ under the ticker symbol "KRTX."

Who are Karuna Therapeutics' major shareholders?

Karuna Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.10%), BlackRock Inc. (5.44%), State Street Corp (3.44%), Viking Global Investors LP (3.26%), Wellington Management Group LLP (2.86%) and Rock Springs Capital Management LP (1.45%). Company insiders that own Karuna Therapeutics stock include Andrew Craig Miller, Atul Pande, Edmund Harrigan, Heather Preston, James Healy, Laurie J Olson, Puretech Health Llc, Stephen K Brannan, Steven M Paul and Troy A Ignelzi.
View institutional ownership trends for Karuna Therapeutics.

Which major investors are selling Karuna Therapeutics stock?

KRTX stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Farallon Capital Management LLC, First Light Asset Management LLC, Wellington Management Group LLP, Citigroup Inc., Dimensional Fund Advisors LP, Emerald Mutual Fund Advisers Trust, and Eagle Asset Management Inc.. Company insiders that have sold Karuna Therapeutics company stock in the last year include Andrew Craig Miller, Atul Pande, Laurie J Olson, Stephen K Brannan, and Troy A Ignelzi.
View insider buying and selling activity for Karuna Therapeutics or view top insider-selling stocks.

Which major investors are buying Karuna Therapeutics stock?

KRTX stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Lord Abbett & CO. LLC, Bank of New York Mellon Corp, Viking Global Investors LP, Jennison Associates LLC, Victory Capital Management Inc., Woodline Partners LP, and Ghost Tree Capital LLC. Company insiders that have bought Karuna Therapeutics stock in the last two years include Heather Preston, James Healy, and Steven M Paul.
View insider buying and selling activity for Karuna Therapeutics or or view top insider-buying stocks.

How do I buy shares of Karuna Therapeutics?

Shares of KRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Karuna Therapeutics' stock price today?

One share of KRTX stock can currently be purchased for approximately $104.53.

How much money does Karuna Therapeutics make?

Karuna Therapeutics has a market capitalization of $3.12 billion and generates $36.96 million in revenue each year. The company earns $-143.80 million in net income (profit) each year or ($5.780010) on an earnings per share basis.

How many employees does Karuna Therapeutics have?

Karuna Therapeutics employs 118 workers across the globe.

What is Karuna Therapeutics' official website?

The official website for Karuna Therapeutics is karunatx.com.

How can I contact Karuna Therapeutics?

Karuna Therapeutics' mailing address is 33 ARCH STREET SUITE 3110, BOSTON MA, 02110. The company can be reached via phone at (857) 449-2244 or via email at [email protected].